Age-specific prevalence for mf or LF antigen in Dokan Tofa and Piapung sentinel villages.
Frank O. Richards
Abel Eigege
Emmanuel S. Miri
Alphonsus Kal
John Umaru
Davou Pam
Lindsay J. Rakers
Yohanna Sambo
Jacob Danboyi
Bako Ibrahim
Solomon E. Adelamo
Gladys Ogah
Danjuma Goshit
O. Kehinde Oyenekan
Els Mathieu
P. Craig Withers
Yisa A. Saka
Jonathan Jiya
Donald R. Hopkins
10.1371/journal.pntd.0001346.g007
https://plos.figshare.com/articles/figure/_Age_specific_prevalence_for_mf_or_LF_antigen_in_Dokan_Tofa_and_Piapung_sentinel_villages_/396500
<p>Panel A: Dokan Tofa pretreatment prevalence by age group (n = 418). Panel B: Piapung pretreatment prevalence by age group (n = 400). Panel C: Dokan Tofa prevalence by age group after 6 rounds of MDA (n = 223). Panel D: Piapung prevalence by age group after 6 rounds of MDA (n = 280). Boxes show numbers sampled in each age group. Pretreatment sample for mf is different from <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001346#pntd-0001346-t002" target="_blank">Table 2</a> because ages were not available on all persons tested. Pretreatment sample for antigen for these SVs are different than baseline figure shown in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001346#pntd-0001346-t003" target="_blank">Table 3</a> because 1999/2000 mapping data were added to baseline calculation in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001346#pntd-0001346-t003" target="_blank">Table 3</a> (see <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001346#s2" target="_blank">Methods</a>).</p>
2013-02-20 13:56:25
prevalence
mf
lf
antigen
dokan
tofa
piapung
sentinel